Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

Gynecologic Oncology
Angeles Alvarez SecordGynecologic Oncology Group

Abstract

This phase II trial assessed the activity and tolerability of cetuximab (C225, Erbitux) in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma. Patients were to receive combination therapy with cetuximab (initial dose of 400 mg/m2 intravenously on cycle 1, day 1, followed by weekly infusions of 250 mg/m2) and carboplatin (AUC of 6 on day 1 and every 3 weeks). The primary objectives of this trial were to estimate the anti-tumor activity and adverse events of this combination therapy. Immunohistochemical expression of EGFR was evaluated in tumor specimens from patients enrolled in this trial. Of the 29 patients, 28 (97%) were eligible and evaluable for analysis of the efficacy and toxicity of cetuximab administered in combination with carboplatin. Of the evaluable entries, 26 had EGFR-positive tumors and the response rate in this group of patients was as follows: 9 demonstrated an objective response (3 CR; 6 PR) and 8 had stable disease. The response rate did not meet criteria for opening a second stage of accrual. The median time to progression was 9.4+ months (range: .9-22.2+). The most commonly observed adverse events were dermatologic toxicity (grade 3 in 32%), thr...Continue Reading

References

Nov 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·M PrewettN I Goldstein
Aug 1, 1997·Gynecologic Oncology·J V IlekisB Scoccia
Nov 20, 1998·Statistics in Medicine·T T Chen, T H Ng
Sep 21, 2001·Journal of Pediatric Hematology/oncology·D Y YuP G Fisher
Jun 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George A OmuraSusan G Arbuck
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony T C ChanAlex Y Chang
Apr 21, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J PfistererUNKNOWN EORTC GCG
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstMerrill S Kies
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christiane D ThieneltKaren Kelly
Nov 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco RobertMichael Needle
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara BurtnessUNKNOWN Eastern Cooperative Oncology Group

❮ Previous
Next ❯

Citations

Jan 10, 2014·Molecular Diagnosis & Therapy·Henry D ReyesKimberly K Leslie
Jan 12, 2012·Clinical & Developmental Immunology·Filippo BellatiMarianna Nuti
Jan 12, 2012·Journal of Oncology·Tomoko TagawaJoanne Mortimer
Oct 5, 2010·Women's Health·T S KristedjaM Cristea
Jan 13, 2010·Journal of Oncology·Reema ZeineldinLaurie G Hudson
Jan 5, 2011·Frontiers in Bioscience (Scholar Edition)·Amy R CarrollAnil K Sood
Jul 1, 2011·Chemical Communications : Chem Comm·Sanjib BhattacharyyaPriyabrata Mukherjee
Jul 26, 2011·BMC Cancer·Ashley StuckeyAlexander S Brodsky
Jun 5, 2012·Investigational New Drugs·Shannon N WestinRobert L Coleman
Apr 22, 2009·Current Treatment Options in Oncology·Ernest S HanMark Wakabayashi
Feb 5, 2013·Expert Opinion on Biological Therapy·Umberto Leone Roberti MaggioreSimone Ferrero
Sep 1, 2010·Expert Opinion on Medical Diagnostics·Gernot KriegshäuserRobert Zeillinger
Apr 7, 2010·Expert Opinion on Investigational Drugs·Liz Y HanStan B Kaye
Feb 11, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Priyanka BhattRajashree Mashru
Nov 26, 2013·Nuclear Medicine and Biology·Tuulia HuhtalaAle Närvänen
Apr 24, 2012·Hematology/oncology Clinics of North America·Behrouz ZandAnil K Sood
Aug 3, 2010·Critical Reviews in Oncology/hematology·Kyriaki Pliarchopoulou, Dimitrios Pectasides
Feb 24, 2009·Gynecologic Oncology·Peter J FrederickDonald J Buchsbaum
Jan 30, 2010·Journal of Oncology·Nicanor I Barrena MedelThomas J Herzog
Sep 30, 2014·Journal of Experimental & Clinical Cancer Research : CR·Yi YuCongjian Xu
Apr 28, 2011·CA: a Cancer Journal for Clinicians·Danijela Jelovac, Deborah K Armstrong
Apr 17, 2016·Critical Reviews in Oncology/hematology·Wen XuJermaine I G Coward
Mar 5, 2016·Expert Review of Anticancer Therapy·Jennifer McLachlanSusana Banerjee
Mar 26, 2015·Journal for Immunotherapy of Cancer·Cariad ChesterHolbrook Kohrt
Jul 7, 2014·Journal of Cancer Research and Clinical Oncology·Xia LiuFuqiang Yin
Oct 21, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Majid MomenySeyed H Ghaffari
Sep 13, 2014·Cancer Chemotherapy and Pharmacology·Alvaro Henrique Ingles GarcesAndréia Cristina de Melo
Nov 10, 2016·Expert Review of Molecular Diagnostics·Rebecca A PrevisShannon N Westin
Mar 13, 2018·Expert Opinion on Emerging Drugs·Luisa BonillaStephanie Lheureux
May 7, 2013·International Journal of Molecular Sciences·Elisabeth SmolleJohannes Haybaeck
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Krishnayan HaldarJo Morrison
Oct 15, 2018·Journal of Cellular Physiology·Vahideh TarhrizShirin Eyvazi
Oct 16, 2018·The Cochrane Database of Systematic Reviews·Jo MorrisonAndrew Bryant
Dec 6, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Karina Dahl SteffensenAnders Jakobsen
Aug 18, 2009·Journal of Experimental & Clinical Cancer Research : CR·Jeffrey B HoagMark E Lund
Jan 7, 2009·Current Opinion in Obstetrics & Gynecology·Fiona Collinson, Gordon Jayson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

© 2021 Meta ULC. All rights reserved